Immunohistochemistry and Molecular Pathology
Immunohistochemistry and molecular pathology in adrenocortical carcinoma (ACC) comprise the tissue-based methods used to confirm adrenocortical origin, characterize tumor biology, and relate morphologic findings to prognosis and emerging therapeutic research. Within ACC care, these approaches sit downstream of radiology and endocrine evaluation and are most central to surgical pathology, differential diagnosis, grading, and translational stratification. Their practical role is therefore not singular: some markers address lineage, others estimate proliferative or tumor-suppressor abnormalities, and others describe pathway activation or molecular subtypes that may have biologic or investigational relevance.
The evidence base is uneven. A small number of marker classes are embedded in routine pathology workflows, but much of the broader molecular pathology literature is derived from retrospective series, reference-center cohorts, and translational studies with limited external validation. Even when immunohistochemical or molecular abnormalities are recurrent, they do not by themselves establish malignancy in isolation and usually need to be interpreted alongside morphology, clinical context, and established diagnostic scoring systems. Indirect evidence from normal adrenal tissue or benign adrenocortical tumors may clarify biologic context, but it has limited reliability for direct ACC diagnosis or prognostication.12
A useful way to organize this topic is by the clinical question being asked: whether a tumor is of adrenocortical lineage, whether tissue findings suggest more aggressive behavior, whether a pathway-linked marker adds biologic or therapeutic insight, and how these findings should be captured in structured reports. This framework reflects current practice more closely than a chronological reading of the literature and helps separate relatively established pathology tasks from more exploratory biomarker work.
Diagnostic context
In ACC, immunohistochemistry is principally an adjunct to histomorphology rather than a replacement for it. The most reliable tissue-based application is confirmation of adrenocortical differentiation in an appropriate differential diagnosis, particularly when distinguishing primary adrenal cortical neoplasms from metastatic tumors or other adrenal-region malignancies. By contrast, no single immunostain or molecular assay definitively establishes carcinoma status independent of morphology and clinicopathologic correlation.
This distinction is important clinically: lineage markers may support that a tumor is adrenocortical, but they do not resolve all questions about benign versus malignant behavior. Conversely, molecular abnormalities may be biologically informative yet remain insufficiently validated for standalone diagnostic use. The practical implication is that pathology interpretation remains integrated, with immunohistochemistry serving as supporting evidence rather than an autonomous test.
Markers of cortical lineage
Markers of cortical lineage are used to support adrenocortical origin and are most useful in differential-diagnostic settings. In practice, this category includes steroidogenic and adrenal cortical markers used in panels rather than in isolation, because no single marker is perfectly sensitive or specific across the full range of tumors encountered in adrenal pathology. Reliability is greatest when several concordant markers are interpreted together with morphology.
Some steroidogenic enzymes are better understood as markers of functional zonation than of carcinoma identity. For example, CYP11B1 and CYP11B2 help map cortisol- and aldosterone-associated differentiation patterns in normal adrenal cortex and benign adrenocortical lesions, which may provide biologic background for tumor interpretation; however, the direct applicability of these zonation studies to ACC is limited because they do not primarily study carcinoma.1 Clinically, such markers may help contextualize functional differentiation, but they should not be overinterpreted as validated standalone ACC markers.
Negative boundaries are also relevant in this area. HSD3B1 participates in steroidogenesis, but available indirect evidence does not support it as an established marker of adrenocortical lineage: normal adrenal tissue was negative in a broad survey, and only weak focal expression was seen in a minority of adrenocortical adenomas.2 Because ACC was not directly studied, this is best understood as a caution against assuming that all steroidogenic enzymes are diagnostically useful cortical markers. The practical implication is that marker selection should follow validated adrenal pathology panels rather than pathway logic alone.2
Proliferation, tumor-suppressor, and biologic-risk markers
Once adrenocortical origin is established, pathology work often shifts toward markers that may correlate with biologic aggressiveness. This includes proliferative indices and immunohistochemical surrogates of tumor-suppressor pathway disruption. In broad terms, these markers are more relevant to risk stratification and research correlation than to primary lineage assignment.
What is relatively reliable is the general principle that proliferative activity and major pathway disruption may track with more aggressive disease biology. What is less reliable is the exact thresholding, reproducibility across laboratories, and independent prognostic value of individual markers when separated from stage, resection status, and conventional histopathology. Clinically, these markers may inform multidisciplinary discussion and research categorization, but they usually supplement rather than override standard prognostic frameworks.
Pathway and expression markers
A separate group of studies examines pathway-linked or expression-based markers that sit between diagnostic pathology and translational oncology. These markers may reflect recurrent biologic themes in ACC, such as altered signaling, growth-factor dysregulation, or immune-related expression patterns. Their main value is in describing tumor biology and generating hypotheses for subtype definition or therapeutic targeting.
The most dependable conclusion from this literature is that ACC is biologically heterogeneous and that tissue markers may capture parts of that heterogeneity. The least dependable conclusion is that any one expression marker currently has broad, routine clinical utility across centers. In practice, pathway markers may be useful in specialist review, correlative studies, or trial-oriented work, but most remain investigational from a day-to-day management perspective.
Structured reporting and molecular integration
As the field has expanded beyond morphology alone, structured reporting has become increasingly important for comparability across institutions. Standardized datasets help ensure that core pathologic variables, immunohistochemical findings, and relevant molecular results are recorded consistently, which is especially important in a rare tumor such as ACC where evidence often depends on pooled or multicenter experience.
This is one of the more reliable themes in the literature: standardization improves interpretability even when individual biomarkers remain imperfect. The practical implication is that integrated reporting may be more immediately useful than adding large numbers of poorly validated markers, because it strengthens communication between pathology, surgery, endocrinology, and oncology.
Limitations and pitfalls
Several recurring limitations shape interpretation of the ACC immunohistochemistry and molecular pathology literature. Much of the evidence comes from retrospective series, selected referral populations, and exploratory biomarker studies, which may overestimate performance and reduce generalizability. Rare-tumor constraints also mean that some candidate markers are supported mainly by indirect evidence, small cohorts, or comparison with normal adrenal tissue rather than by large ACC-specific validation studies.12
A further pitfall is conflating functional differentiation, lineage confirmation, and malignancy assessment. A marker may indicate steroidogenic differentiation without being useful for distinguishing ACC from adenoma, and a biologically interesting molecular alteration may have uncertain incremental value for diagnosis or prognosis. Clinically, this argues for cautious interpretation, prioritization of validated marker panels, and continued reliance on integrated clinicopathologic assessment.
Role in management and research
Overall, immunohistochemistry and molecular pathology contribute to ACC management by refining diagnosis, supporting differential diagnosis, and providing biologic context for prognosis and research. Their strongest current role is in pathology classification and in the structured description of tumor features that may inform multidisciplinary care. Their role is weaker when used as isolated determinants of treatment selection outside specialist or investigational settings.
This balance is likely to remain important as molecular profiling evolves. Tissue biomarkers may eventually help define clinically actionable subgroups, but present evidence still supports a hierarchy in which morphology, staging, and standard clinical workflows remain primary, with immunohistochemical and molecular findings acting as complementary layers of information rather than definitive standalone arbiters.12
Included Articles
- PMID 20200334: This study established immunohistochemical localization of CYP11B1 and CYP11B2 in human adrenal tissue, showing variegated zonation and aldosterone-producing cell clusters. For ACC, it is mainly useful as background on steroidogenic expression markers and functional differentiation rather than as a direct carcinoma study.1
- PMID 23318910: PMID 23318910 evaluated HSD3B1 across a wide range of tumors and found no expression in normal adrenal tissue, with only weak focal staining in 2 of 12 adrenocortical adenomas. Although ACC was not studied directly, the paper is relevant as an indirect caution that HSD3B1 is not established as a marker of adrenocortical lineage despite its role in steroidogenesis.2
References
Footnotes
-
Adrenocortical zonation in humans under normal and pathological conditions.. J Clin Endocrinol Metab. 2010. PMID: 20200334. Local full text: 20200334.md ↩ ↩2 ↩3 ↩4 ↩5
-
HSD3B1 is a specific trophoblast-associated marker not expressed in a wide spectrum of tumors.. Int J Gynecol Cancer. 2013. PMID: 23318910. Local full text: 23318910.md ↩ ↩2 ↩3 ↩4 ↩5 ↩6